Glycogen Synthase Kinase 3 Is a Potential Drug Target for African Trypanosomiasis Therapy
暂无分享,去创建一个
Timothy N C Wells | M. Gelb | F. Buckner | Aaron Riechers | C. Verlinde | Mathias M. Domostoj | A. Scheer | W. V. Van Voorhis | K. Ojo | Alexander Scheer | Frederick S Buckner | Michael H Gelb | Wesley C Van Voorhis | A. Napuli | T. Wells | J Robert Gillespie | Christophe L M J Verlinde | Alberto J Napuli | J. R. Gillespie | Susan Wells | Kayode K Ojo | Aaron J Riechers | Mathias M Domostoj | Susan J Wells
[1] C. Naula,et al. Protein kinases as drug targets in trypanosomes and Leishmania. , 2005, Biochimica et biophysica acta.
[2] Ching C. Wang,et al. Pairwise Knockdowns of cdc2-Related Kinases (CRKs) in Trypanosoma brucei Identified the CRKs for G1/S and G2/M Transitions and Demonstrated Distinctive Cytokinetic Regulations between Two Developmental Stages of the Organism , 2005, Eukaryotic Cell.
[3] J. Mottram,et al. The Trypanosoma brucei Cyclin, CYC2, Is Required for Cell Cycle Progression through G1 Phase and for Maintenance of Procyclic Form Cell Morphology* , 2004, Journal of Biological Chemistry.
[4] S. Knapp,et al. Crystal Structures of the p21-Activated Kinases PAK4, PAK5, and PAK6 Reveal Catalytic Domain Plasticity of Active Group II PAKs , 2007, Structure.
[5] D. Lipman,et al. Improved tools for biological sequence comparison. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[6] R. Kaminsky,et al. The Alamar Blue assay to determine drug sensitivity of African trypanosomes (T.b. rhodesiense and T.b. gambiense) in vitro. , 1997, Acta tropica.
[7] Rick Gussio,et al. Structure‐Aided Optimization of Kinase Inhibitors Derived from Alsterpaullone , 2005, Chembiochem : a European journal of chemical biology.
[8] B. Nare,et al. Inhibitors of casein kinase 1 block the growth of Leishmania major promastigotes in vitro. , 2006, International journal for parasitology.
[9] M. Vignali,et al. A Facile Method for High-throughput Co-expression of Protein Pairs*S , 2004, Molecular & Cellular Proteomics.
[10] A. Fairlamb. Chemotherapy of human African trypanosomiasis: current and future prospects. , 2003, Trends in parasitology.
[11] P. Cohen,et al. GSK3 takes centre stage more than 20 years after its discovery. , 2001, The Biochemical journal.
[12] Laurent Meijer,et al. Plasmodium falciparum glycogen synthase kinase-3: molecular model, expression, intracellular localisation and selective inhibitors. , 2004, Biochimica et biophysica acta.
[13] H Hirumi,et al. Continuous cultivation of Trypanosoma brucei blood stream forms in a medium containing a low concentration of serum protein without feeder cell layers. , 1989, The Journal of parasitology.
[14] Christine Clayton,et al. A doubly inducible system for RNA interference and rapid RNAi plasmid construction in Trypanosoma brucei. , 2005, Molecular and biochemical parasitology.
[15] Jeffrey Jie-Lou Liao,et al. Molecular recognition of protein kinase binding pockets for design of potent and selective kinase inhibitors. , 2007, Journal of medicinal chemistry.
[16] Wim G J Hol,et al. Heterologous expression of proteins from Plasmodium falciparum: results from 1000 genes. , 2006, Molecular and biochemical parasitology.
[17] P. Greengard,et al. Pharmacological inhibitors of glycogen synthase kinase 3. , 2004, Trends in pharmacological sciences.
[18] P. Greengard,et al. Structural basis for the synthesis of indirubins as potent and selective inhibitors of glycogen synthase kinase-3 and cyclin-dependent kinases. , 2004, Journal of medicinal chemistry.
[19] J. Mottram,et al. The cell cycle of parasitic protozoa: potential for chemotherapeutic exploitation. , 2003, Progress in cell cycle research.
[20] Mark C. Field,et al. RNAit: an automated web-based tool for the selection of RNAi targets in Trypanosoma brucei. , 2003, Molecular and biochemical parasitology.
[21] L. Meijer,et al. Inhibitors of Leishmania mexicana CRK3 Cyclin-Dependent Kinase: Chemical Library Screen and Antileishmanial Activity , 2004, Antimicrobial Agents and Chemotherapy.
[22] G. Cross,et al. Trypanosoma brucei , 1998 .
[23] G. Cross,et al. Rapid isolation of DNA from trypanosomatid protozoa using a simple 'mini-prep' procedure. , 1993, Molecular and biochemical parasitology.
[24] J. Mottram,et al. Stage-specific Differences in Cell Cycle Control in Trypanosoma brucei Revealed by RNA Interference of a Mitotic Cyclin* , 2003, Journal of Biological Chemistry.
[25] R. Pink,et al. Opportunities and Challenges in Antiparasitic Drug Discovery , 2005, Nature Reviews Drug Discovery.
[26] P. C. Chin,et al. Inhibition of neuronal apoptosis by the cyclin‐dependent kinase inhibitor GW8510: Identification of 3′ substituted indolones as a scaffold for the development of neuroprotective drugs , 2005, Journal of neurochemistry.
[27] A. Depaoli-Roach,et al. Glycogen synthase kinase-3 beta is a dual specificity kinase differentially regulated by tyrosine and serine/threonine phosphorylation. , 1994, The Journal of biological chemistry.
[28] Laurence H. Pearl,et al. Crystal Structure of Glycogen Synthase Kinase 3β Structural Basis for Phosphate-Primed Substrate Specificity and Autoinhibition , 2001, Cell.
[29] J. Woodgett,et al. Mitogen inactivation of glycogen synthase kinase-3 beta in intact cells via serine 9 phosphorylation. , 1994, The Biochemical journal.
[30] Colin McMartin,et al. QXP: Powerful, rapid computer algorithms for structure-based drug design , 1997, J. Comput. Aided Mol. Des..
[31] J. Woodgett,et al. Glycogen synthase kinase-3: functions in oncogenesis and development. , 1992, Biochimica et biophysica acta.
[32] F. Dautry,et al. Northern blot normalization with a 28S rRNA oligonucleotide probe. , 1989, Nucleic acids research.